This portion of our website contains archival information. Archived information should be considered accurate only as of the date listed next to the event. Archived information may be superseded by more recent information we have disclosed in later presentations, press releases, filings with the Securities and Exchange Commission or otherwise. Archived information may contain forward-looking statements. Actual results may materially differ based on several factors, including those described in the archived information, press releases and our filings with the SEC.
2010 | 2009 | 2008 | 2007 | 2006 |
- December 10, 2007
Targacept to Receive $6 Million from GlaxoSmithKline for Initiation of Phase I Trial of Neuropathic Pain Candidate - December 03, 2007
Targacept Announces Results of Phase II Study of TC-2696 in Postoperative Dental Pain - November 29, 2007
Targacept Announces Addition of Julia R. Brown to its Board of Directors - November 08, 2007
Targacept Reports Third Quarter 2007 Financial Results - November 05, 2007
Targacept to Receive $2 Million from AstraZeneca for Option to Lead Product Candidate in Alpha7 NNR Program - October 30, 2007
Targacept to Report Third Quarter Results on November 8, 2007 - October 29, 2007
Targacept to Present at CIBC and Lazard Investor Conferences - October 26, 2007
Targacept Scientists to Present at the 37th Annual Meeting of the Society for Neuroscience - October 23, 2007
Targacept Announces Plans to Develop Enantiomer of Mecamylamine as Augmentation Therapy for Depression - September 26, 2007
Targacept to Present at Three Upcoming Investor Conferences - August 31, 2007
Targacept to Present at BioCentury Newsmakers and Bear Stearns Conferences - August 23, 2007
Targacept Announces Initiation of Phase IIb Development of AZD3480 (TC-1734) for Cognitive Deficits in Schizophrenia - August 07, 2007
Targacept Reports Second Quarter 2007 Financial Results - August 01, 2007
Targacept to Report Second Quarter Results on August 7, 2007 - July 27, 2007
Targacept to Host Conference Call Today at 10:00 a.m. on GlaxoSmithKline Product Development Alliance - July 27, 2007
GlaxoSmithKline and Targacept Form Alliance in Therapeutics for CNS-related Disorders - July 26, 2007
Targacept Initiates Phase I Clinical Trial of TC-5619 - July 24, 2007
Targacept Presents Data from TRIDMAC™ Trial Showing Positive Effects of Mecamylamine as Augmentation Treatment for Depressed Patients - July 23, 2007
Targacept Announces Initiation of Phase IIb Development of AZD3480 (TC-1734) for Alzheimer’s Disease - June 14, 2007
Targacept Announces Addition of Ralph Snyderman, M.D. to its Board of Directors - May 31, 2007
Targacept to Present at Bear Stearns Biotech Confab - May 14, 2007
Targacept Invited to Testify at Congressional Hearing on Current and Future Breakthrough Research in Alzheimer’s Disease - May 09, 2007
Targacept Reports First Quarter 2007 Financial Results - April 25, 2007
Targacept to Report First Quarter 2007 Financial Results on May 9, 2007 - March 22, 2007
Targacept to Present at Upcoming Investor Conferences - February 22, 2007
Targacept Reports Fourth Quarter and 2006 Financial Results - February 12, 2007
Targacept to Report Fourth Quarter and Full Year 2006 Results on February 22, 2007 - February 05, 2007
Targacept to Present at BIO CEO and Investor Conference - January 08, 2007
Targacept Initiates Phase I Clinical Trial of TC-2216